Avalo Therapeutics, Inc. announced the appointment of Dr. June Almenoff, effective November 10, 2021, and Mitchell Chan, effective December 1, 2021 as independent members of its Board of Directors. These two new independent directors are replacing Dr. Suzanne Bruhn and Philip Gutry. June Almenoff M.D., Ph.D., is an accomplished biopharma executive with close to 25 years of leadership experience. She brings expertise in R&D, commercialization, and executive leadership to this role. Dr. Almenoff served as President and Chief Medical Officer of Furiex Pharmaceuticals, which was acquired by Actavis for $1.2 billion. Furiex developed eluxadoline (Viberzi(R)), which was approved both in the United States and Europe. Dr. Almenoff is currently Chief Medical Officer at RedHill Biopharma Ltd, where she serves on the commercial executive team. Mitchell Chan has more than 15 years of finance experience in the life sciences industry. Mr. Chan was previously the Chief Financial Officer at Viela Bio, where he was instrumental in supporting the company through capital raises with leading global healthcare investors. While at Viela Bio, he successfully raised over $750 million including an initial public offering in 2019. In 2021, he also led a merger transaction whereby Viela Bio was acquired by Horizon Therapeutics for $3.1 billion. Prior to Viela Bio, Mr. Chan served as the Director of Investor Relations for AstraZeneca, North America. Mr. Chan also held several roles of increasing responsibility at Genentech-Roche including in BioOncology Commercial Finance, R&D Finance, and Mergers & Acquisitions.